A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection

Arch Dermatol. 2005 Feb;141(2):177-80. doi: 10.1001/archderm.141.2.177.

Abstract

Objective: To determine the frequency at which the CDKN2A coding region is mutated in the atypical nevi of persons with sporadic melanoma.

Design: DNA samples, isolated by laser-captured microdissection of atypical nevi from 10 patients with newly incident cases of sporadic melanoma and their spouses as matched controls, were used as templates for nested polymerase chain reaction amplification of CDKN2A exons 1 and 2.

Results: No point mutations in the coding region of CDKN2A were observed in any of the melanocytic nevi.

Conclusions: Point mutations in CDKN2A are an uncommon event in the atypical nevi of persons with melanoma. As such, the data may support a hypothesis of melanocytic nevus histogenesis, in which the melanocytic nevus and malignant melanoma represent separate, pleiotropic pathways resulting from common stimuli, such as genomic damage from UV radiation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alleles
  • Base Sequence
  • Case-Control Studies
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • DNA, Neoplasm / analysis
  • Diagnosis, Differential
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genetic Predisposition to Disease*
  • Humans
  • Laser Therapy / methods
  • Male
  • Melanoma / genetics*
  • Melanoma / pathology
  • Melanoma / surgery
  • Microdissection / methods
  • Molecular Sequence Data
  • Nevus, Pigmented / genetics*
  • Nevus, Pigmented / pathology
  • Nevus, Pigmented / surgery
  • Paraffin Embedding
  • Point Mutation*
  • Polymerase Chain Reaction / methods
  • Probability
  • Reference Values
  • Sampling Studies
  • Sensitivity and Specificity
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / surgery

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • DNA, Neoplasm